Holocene Advisors LP Decreases Position in DexCom, Inc. (NASDAQ:DXCM)

Holocene Advisors LP lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 98.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,553 shares of the medical device company's stock after selling 1,743,682 shares during the quarter. Holocene Advisors LP's holdings in DexCom were worth $1,981,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the second quarter worth approximately $25,000. Sachetta LLC lifted its position in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after purchasing an additional 171 shares during the last quarter. Riverview Trust Co grew its stake in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares in the last quarter. DT Investment Partners LLC grew its stake in shares of DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after purchasing an additional 315 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new position in DexCom in the third quarter valued at $57,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 426 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by corporate insiders.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $1.20 during midday trading on Friday, hitting $77.72. The stock had a trading volume of 2,644,207 shares, compared to its average volume of 3,793,395. The company has a market capitalization of $30.36 billion, a PE ratio of 46.54, a P/E/G ratio of 2.48 and a beta of 1.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a 50 day moving average price of $72.55 and a two-hundred day moving average price of $86.05. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on DXCM shares. Raymond James lowered their price objective on DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research report on Friday, October 25th. Oppenheimer lowered their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Stifel Nicolaus raised their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, August 23rd. StockNews.com downgraded shares of DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Finally, Royal Bank of Canada dropped their price objective on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.